TAK-881, HyQvia 100 mg/mL solution for infusion for subcutaneous use, HyQvia 100 mg/mL solution for infusion for subcutaneous use
TAK-881-3003
Phase 3 small_molecule active
Quick answer
TAK-881, HyQvia 100 mg/mL solution for infusion for subcutaneous use, HyQvia 100 mg/mL solution for infusion for subcutaneous use for Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active